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This preclinical study investigated the therapeutic efﬁcacy of electroporation (EP)-based delivery
of plasmid DNA (pDNA) encoding viral proteins (envelope, core) and IFN-g in the duck model of chronic
hepatitis B virus (DHBV) infection. Importantly, only DNA EP-therapy resulted in a signiﬁcant decrease
in mean viremia titers and in intrahepatic covalently closed circular DNA (cccDNA) levels in chronic
DHBV-carrier animals, compared with standard needle pDNA injection (SI). In addition, DNA
EP-therapy stimulated in all virus-carriers a humoral response to DHBV preS protein, recognizing a
broader range of major antigenic regions, including neutralizing epitopes, compared with SI. DNA
EP-therapy led also to signiﬁcant higher intrahepatic IFN-g RNA levels in DHBV-carriers compared to
other groups, in the absence of adverse effects. We provide the ﬁrst evidence on DNA EP-therapy
beneﬁt in terms of hepadnaviral infection clearance and break of immune tolerance in virus-carriers,
supporting its clinical application for chronic hepatitis B.
& 2012 Elsevier Inc. All rights reserved.Introduction
Despite the existence of an effective prophylactic vaccine,
chronic hepatitis B virus (HBV) infections remain a major public
health problem (Zoulim, 2011). The failure of current antiviral
therapies (interferon alpha, nucleoside analogs) is related to their
limited ability to completely eliminate the intranuclear covalently
closed circular DNA (cccDNA), viral minichromosome that repre-
sent the transcriptional template of HBV replication (Zoulim,
2011). Several studies reported that the clearance of acute HBV
infection relies on the development of appropriate immune
responses against HBV, including protective, virus neutralizing
antibodies against HBV surface antigen (HBsAg), antigen-speciﬁc
T-helper (Th) cells and cytolytic T lymphocytes (CTL) associatedll rights reserved.
lbert Thomas, 69424, Lyonwith an upregulated expression of type 1 inﬂammatory cytokines
in the liver, especially gamma interferon (IFN-g) (Bertoletti and
Ferrari, 2003; Chisari and Ferrari, 1995; Ferrari et al., 1990;
Guidotti and Chisari, 2001; Jung et al., 1995; Lohr et al., 1995;
Marinos et al., 1995; Rehermann, 2000; Wang et al., 2003).
Studies in HBV-transgenic mice demonstrated the crucial role of
IFN-g in the non-cytolytic mechanism of virus clearance (Guidotti
and Chisari, 2001; Wieland and Chisari, 2005). In addition, such
IFN-g-mediated control of infection was demonstrated during
recovery from acute HBV infection of chimpanzees and wood-
chuck HBV (WHV) infection of woodchucks (Guidotti et al., 1999;
Hodgson and Michalak, 2001; Wieland et al., 2004). In this
context, it has been shown that IFN-g is highly effective in
steering T-cell responses towards the Th1 type during resolution
of infection. In contrast, the chronic HBV infection is accompanied
by weak and narrowly focused HBV-speciﬁc humoral and cellular
immune responses. Thus, therapeutic DNA vaccination, able to
activate both defective humoral and Th1 cellular immune
responses in HBV carriers, has been proposed as a particularly
G. Khawaja et al. / Virology 433 (2012) 192–202 193pertinent approach for chronic hepatitis B therapy (Cova, 2012;
Michel et al., 2011; Michel and Loirat, 2001). However, the
progress of DNA vaccines into the clinic has been hampered by
the relatively low magnitude and inconsistent immune responses
achieved by conventional DNA delivery methods in non-human
primates and humans (Sardesai and Weiner, 2011). Thus, the
results of the ﬁrst clinical trials of HBV DNA vaccine in chronically
infected patients were rather disappointing, indicating a need to
increase the efﬁcacy of this approach (Cavenaugh et al., 2011).
Electroporation (EP)-mediated delivery appears to be a pro-
mising novel approach to improve the immune responses to DNA
vaccines. EP dramatically enhances the potency of DNA vaccines
by increasing cell membrane permeability, thereby facilitating
cellular uptake of DNA, and also by eliciting a low level inﬂam-
mation, which enhances the inﬂux of antigen-presenting cells to
the injection site (van Drunen Littel-van den Hurk and Hanna-
man, 2010). Recent studies in several animal species (mice, rabbit,
woodchuck, sheep, pig, cattle and rhesus macaques) (Babiuk et al.,
2007; Chen et al., 2011; Donate et al., 2011; Kim et al., 2008; Liu
et al., 2011; Luxembourg et al., 2006; Luxembourg et al., 2008;
Nystrom et al., 2010; Peng et al., 2007; van Drunen Littel-van den
Hurk et al., 2008; Yin et al., 2011; Zhao et al., 2006) convincingly
demonstrated that EP-based delivery of DNA vaccines targeting
HBV envelope and/or core antigens markedly enhanced humoral
and cellular immune responses as compared to those induced by
standard needle injection (SI) of the same DNA vaccine. However,
evaluation of EP-based pDNA delivery in these studies was
limited to analysis of immunogenicity or prophylactic efﬁcacy of
such vaccines in naı¨ve animals. EP-based DNA delivery now has
reached the clinical stage being actively investigated in several
phase I clinical trials for therapeutic and prophylactic application
against cancer (Low et al., 2009) and infectious diseases (Bodles-
Brakhop et al., 2009; Sallberg et al., 2009; Sardesai and Weiner,
2011; van Drunen Littel-van den Hurk and Hannaman, 2010).
Concerning HBV infection, a randomized controlled clinical trial
of EP-mediated HBV DNA vaccine in chronic hepatitis B patients
under lamivudine chemotherapy has been recently performed in
China (Yang et al., 2012), although, its ability to clear intrahepatic
viral cccDNA that cannot be eliminated by current antiviral
therapies, remains unknown.
In this regard, the duck hepatitis B virus (DHBV) represents a
pertinent model to evaluate the therapeutic efﬁcacy of EP-based
pDNA delivery. Thus, the DHBV is a related avian hepadnavirus
with replication strategies and genomic organization closely
related to the human HBV. DHBV played a pivotal role in studying
hepadnavirus replication and testing the impact of novel anti-HBV
therapeutic approaches on intrahepatic viral cccDNA elimination
(Cova, 2012; Cova and Zoulim, 2004; Le Guerhier et al., 2000; Le
Guerhier et al., 2003; Thermet et al., 2008). The experimental
DHBV infection of neonatal ducklings leads to the establishment of
a chronic DHBV-carrier similar to chronic HBV infection in humans
(Cova and Zoulim, 2004; Rollier et al., 1999). Moreover, as for the
resolution of acute HBV infection, the resolution of DHBV infection
in adult ducks is associated with a seroconversion to protective,
virus-neutralizing antibodies, essentially directed against preS
envelope protein and an increased expression of duck interferon-
g (DuIFN-g) in the liver and peripheral blood mononuclear cells
(PBMCs) (Narayan et al., 2006).
We have previously reported in this model that immunother-
apy of chronically infected ducks with SI-delivered DNA vaccine
encoding DHBV proteins (envelope, core), decreased viral replica-
tion and enhanced viral clearance in some animals (Rollier et al.,
1999; Thermet et al., 2008). In addition, we have shown that co-
delivery of DuIFN-g encoding plasmid with the DHBV DNA
vaccine leads to the enhancement of the humoral anti-preS
response in naı¨ve animals (Saade et al., 2008) and enhancedtherapeutic efﬁcacy of DNA vaccine in DHBV-carriers (Saade et al.,
2011).
In our recent study, we have shown that EP-based pDNA
delivery in naı¨ve ducks considerably enhanced the magnitude
and breadth of humoral response to DHBV large envelope protein
(preS/S), which was highly neutralizing as compared with that
induced by the SI administration (Khawaja et al., 2012).
In our efforts to explore whether therapeutic efﬁcacy of a
genetic vaccine targeting hepadnaviral proteins can be enhanced
using EP-based immunization, we carried out a long-term (10
months) follow-up study in chronic DHBV duck model. We
focused here on the ability of EP-based pDNA delivery to sustain-
ably suppress viral infection, including clearance of the intrahe-
patic cccDNA viral form responsible for the persistence of
infection, and to restore antiviral immune responses.Results
EP-based pDNA delivery decreases viremia and enhances break of
humoral immune tolerance in chronically infected ducks
To investigate the long-term therapeutic effect of EP-based
DHBV pDNA vaccine delivery, chronic DHBV-carriers were ran-
domly assigned into three groups. Two of the groups were
immunized intramuscularly (i.m) with a total of 600 mg of the
same DNA vaccine encoding DHBV envelope and core proteins as
well as DuIFN-g, but delivered either by SI or EP. A control group
included untreated ducks and ducks receiving 600 mg of empty
pCI plasmid. The immunized animals received additional DNA
vaccine administrations every 3–7 weeks during 10 months of
follow-up. Analysis of serum DHBV DNA collected prior to
immunization (weeks 1–3 of age) showed no signiﬁcant differ-
ence between the mean viremia levels of the different duck
groups. By contrast, starting from the third DNA administration
(week 10), the EP-treated group showed a marked decrease in
mean viremia levels, which reached a signiﬁcant difference as
compared to SI-treated and to the control group starting from
week 31 to the end of the experiment at week 40 (po0.05)
(Fig. 1G). This viremia decrease in the EP-treated group was
largely due to 2 animals: duck no. 474 exhibited an early drop
in viremia starting at week 10 that became undetectable from
week 16 and duck no. 454 that cleared serum viral DNA after
week 37, as illustrated on individual viremia titers follow-up
(Fig. 1C). Importantly, viremia levels remained undetectable in
these animals following immunotherapy cessation and upto the
end of the follow-up, indicating a sustained effect (Fig. 1C). The
remaining animals from the EP-treated group (nos. 440, 452, 475
and 459) responded also to the therapeutic vaccination by
exhibiting 1.5 to 2.3 log10-fold decrease in viremia titers at week
40 as compared to pre-treatment levels (week 1). By contrast,
none of the ducks from the SI-treated group or the control group
cleared viral DNA levels in their sera (Fig. 1A and B). Although the
SI-treated group showed higher mean viremia levels as compared
to the control group, the difference was not signiﬁcant and was
essentially due to two animals (nos. 470 and 473) exhibiting
viremia ﬂuctuations or rebounds during the therapy that con-
tributed to increase in mean titers in the group (Fig. 1B and G).
Taken together, these results indicate a signiﬁcant beneﬁt of EP-
based pDNA delivery by sustained decreasing serum viral load as
compared with other groups.
To evaluate whether the anti-envelope antibody response,
generally weak or undetectable in chronic-DHBV carriers, could
be enhanced by pDNA EP therapy, we monitored the anti-preS
antibody titers during the entire experimental period. As shown
in Fig. 1H, the EP-treated group showed a strong and sustained
Fig. 1. Monitoring of viremia and anti-preS titers in chronic DHBV-carriers. Viremia and anti-preS titers were monitored throughout the entire experiment and titers are
plotted on the graphs using a log scale. Individual viremia and anti-preS titers are represented for control ducks (panels A and D, respectively), SI-treated ducks (panels B
and E, respectively) and EP-treated ducks (panels C and F, respectively). The mean viremia and anti-preS titers for each group are shown in panels G and H, respectively.
Black arrows indicate DNA injections at weeks 3, 6, 9, 16, 21, 25, 29, 33 and 36. The dotted line indicates the cut-off detection level of the assays.
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G. Khawaja et al. / Virology 433 (2012) 192–202 195mean anti-preS response. By week 29 and until the end of the
experiment, this response was signiﬁcantly higher (4–34 fold) as
compared to those of SI-treated and control groups (po0.05). The
follow-up of individual anti preS titers within this group, indi-
cated that two animals (no. 474 and 454) mounted a particularly
high anti-preS response (by week 10 and 30, respectively), which
was concomitant with serum viral DNA clearance (Fig. 1F and C).
The remaining EP-treated ducks (4 out of 6) mounted a high anti-
preS response (reaching titers of 1280–2560) at the end of the
follow-up, even though they did not completely clear viral DNA
(Fig. 1F). By contrast, two (no. 470 and 473) out of ﬁve SI-treated
ducks and all control ducks showed very weak anti-preS
responses not exceeding a titer of 160 (Fig. 1D and E).These data
indicate that EP-based DNA delivery induced a break in humoral
immune tolerance against the preS protein in DHBV carriers.AR2
AR3
AR5
AR6
AR1
AR4
AR2
AR3
AR5
Fig. 2. Screening of induced antibodies in ducks for pre-S B cell epitope recognition by p
(A) EP, (B) SI or (C) from control ducks, were taken at the end of the follow-up (wee
covering the entire DHB pre-S region (1–161 aa). Note that the comparison of reacting s
broader anti-preS response for ducks from EP-immunized group as compared with SI-im
analysis, are shown. Background signal of control and nonreactive peptides was subtrac
antigenic regions (AR).Induction of a broader repertoire of anti-preS responses by EP-based
DNA delivery
To investigate the epitope pattern of antibodies generated in
animals from different groups we compared, by peptide scanning
analysis, the major antigenic pre-S regions (ARs) and pre-S
neutralizing epitopes recognized by these antibodies. The scans
in Fig. 2 illustrate the reactivity of sera (week 40) from the EP-
treated, SI-treated, and control groups (panels A, B and C respec-
tively) obtained with overlapping 9-mer peptides spanning the
entire DHB pre-S region (peptides 1–77). All sera from EP-treated
ducks recognized 14 major antigenic regions: AR1 (aa 1–17), AR2
(aa 15–31), AR3 (aa 27–47), AR4 (aa 41–53), AR5 (aa 53–65), AR6
(aa 65–81), AR7 (aa 79–95), AR8 (aa 93–107), AR9 (aa 101–117),
AR10 (aa 115–127), AR11 (aa 121–133), AR12 (aa 135–151), AR13AR13AR7
AR8
AR10
AR14
AR12
AR9 AR11
AR13
AR7
AR8
AR10
AR8
epscan analysis. Sera from immunized ducks with DHBV DNA vaccine delivered by
k 40) and were screened for their reactivity with 77 overlapping 9-mer peptides
pectrum of sera from animals exhibiting similar ELISA titers (640–1280) showed a
munized group. Cumulative optical density values, as determined by the pepscan
ted before graphic representation. AR1 to AR14 indicate the positions of recognized
G. Khawaja et al. / Virology 433 (2012) 192–202196(aa 135–151) and AR14 (aa 145–159). Although there were some
differences in the individual bird to bird responses, the responses
in the ducks that controlled but did not clear virus were generally
very similar to that of ducks (no. 454 and 474) that exhibited
a high seroconversion concomitantly with viremia clearance
(Fig. 2A). Interestingly, the antibodies induced in these EP-
treated ducks were highly reactive to the ARs (2, 4, 7, 8, 10 and
11) that represent the neutralization epitopes 12R-P30, 41P-T52, 83I-
P90, 100F-R107, 112T-P120, 123K-G133 and 58T-W65, respectively, that
were previously identiﬁed by us and others (Chassot et al., 1993;
Yuasa et al., 1991). By contrast, the reactivity spectrum of sera
within the SI-immunized group appeared narrower, of lower
magnitude and was restricted to fewer ARs (2, 3, 5, 7, 8, 10 and
13) as compared to that from EP-treated ducks (Fig. 2B). The sera
of control ducks showed an extremely narrow B-cell epitope
response pattern, which was limited to only one AR (8) (Fig. 2C).
Overall, these results indicate that unlike DNA SI therapy, the
EP-based pDNA delivery was able to break humoral tolerance and
generate in all chronic DHBV-carriers a broadly reactive humoral
response to DHBV preS protein able to recognize several neutra-
lizing epitopes.Fig. 4. Intrahepatic viral cccDNA levels. Detection of DHBV cccDNA was per-
formed by a speciﬁc real-time PCR in necropsy liver samples from all animals. The
detection limit of this assay was 0.0001 cccDNA copies per cell. Horizontal bars
represent mean cccDNA level per group. Statistically signiﬁcant difference in mean
cccDNA levels in the EP group (K) compared the SI group (D) n (po0.05) and to
the control group (’) nn (po0.01) are shown as assessed by two-tailed Mann–
Whitney test.EP-based pDNA delivery enhances intrahepatic viral DNA clearance
At the end of the 10-month follow-up period, we examined the
impact of the immunotherapy on intrahepatic viral DNA in
necropsy liver samples. Southern blot analysis of total intrahepa-
tic DHBV DNA showed that control ducks (3 untreated and
2 empty vector-treated) had similarly high levels of replicative
viral DNA intermediates (Fig. 3). In the duck group treated with
SI-delivered DNA vaccine, none of the animals eliminated DHBV
DNA. Within this group, one (no. 468) out of 5 animals showed
low levels of DHBV DNA replicative forms, however 2 (nos. 470,
473) out of 5 animals had high DNA levels comparable to those of
the control group. By contrast, all DNA EP-treated animals
showed lower levels of viral DNA replicative forms compared to
the control group. Interestingly, within this group, duck no. 454,
that exhibited a relatively late drop in viremia (week 36) showed
very low levels of cccDNA (Fig. 3B). More importantly, duck no.
474 that showed an early drop in viremia levels (week 10),
eliminated all intrahepatic DHBV DNA intermediates, including
the cccDNA form (Fig. 3A). The absence of detectable cccDNA in
the liver of this animal was further conﬁrmed by Southern blot
analysis following an independent non-protein bound cccDNA
extraction (Fig. 3B).
To further examine the persistence of residual traces of
intrahepatic viral DNA, we performed a real-time PCR assay forFig. 3. Effect of DNA immunization on intrahepatic DHBV DNA. Total DNA, was extra
analyzed by Southern blotting. 10 mg of total DNA or cccDNA preparations were subjec
followed by speciﬁc hybridization with a full-length DHBV DNA probe. Control for eq
spectrophotometric quantiﬁcation and by ethidium bromide staining of the correspond
relaxed circular (RC-DNA), single-stranded DNA (ss-DNA) and covalently closed circu
positive of hybridization. (B) Speciﬁc isolation of cccDNA. The black arrow indicates umore precise quantiﬁcation of cccDHBV DNA in these liver
samples. The results indicated that duck no. 474, which had
undetectable liver DHBV DNA replicative forms in Southern
blotting, presented a cccDNA level below the cut-off of the real-
time PCR (i.e. 0.0001 copies/cell), whereas duck no. 454 exhibited
only traces of cccDNA (0.08 copies/cell) (Fig. 4). Moreover, a
signiﬁcant difference in terms of mean cccDNA levels was
observed between EP-treated group and the other groups, i.e.
cccDNA levels being more than 5 and 10-fold lower as compared
to SI-treated group (p¼0.0441) and to control group (p¼0.0043),
respectively suggesting a signiﬁcant beneﬁt of EP-based DNA
delivery on cccDNA pool clearance.EP-based pDNA delivery increases the intrahepatic IFN-g response
To explore the impact of therapies on the intrahepatic expres-
sion of Th1 cytokines, we compared the levels of DuIFN-g
expression in the liver of all animals at the end of the follow-up
period (week 40), using a quantitative RT-PCR. The analysis of
uninfected duck livers showed very low DuIFN-g mRNA amount
(Fig. 5, horizontal bar), which was deﬁned as the baseline level.
Within the control and SI-treated groups, intrahepatic DuIFN-g
RNA levels were almost similar to the baseline level in some
animals or slightly upregulated. By contrast, within the EP-treated
group, an increase in DuIFN-g expression was observed for all
animals, particularly for duck no. 454, which peaked to a highcted at the end of the follow-up (week 40) from all necropsy liver samples and
ted to electrophoresis through 1.5% agarose gels, transferred to nylon membranes
ual cellular DNA loading in all lanes of the corresponding gel was established by
ing gel (data not shown). (A) Analysis of total DHBV DNA. Arrows show position of
lar DHBV DNA (cccDNA). A 3 kb linearized DHBV DNA (*) was used as a control
ndetectable cccDNA.
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cccDNA. Interestingly, the mean values of intrahepatic DuIFN-g
mRNA levels in EP-treated group were signiﬁcantly 10 and
21-fold greater than those of the SI-treated group (p¼0.0043)
and the control group (p¼0.004), respectively. Further analysis of
the intrahepatic DuIFN-g RNA in all DHBV-carriers revealed a
signiﬁcant inverse correlation (r¼0.93, po0.0001) with the
intrahepatic cccDNA levels (supplementary Fig. 1). Thus, the
diminished expression of DuIFN-g in control and nonresponder
ducks within the SI-treated group correlated with the chronic
infection status of these animals that was characterized by a high
level of intrahepatic viral cccDNA. In contrast, the increased
expression of DuIFN-g in all EP-treated ducks and slight increase
in some partial responders to the SI-therapy correlated with
lower levels of cccDNA.Fig. 5. Intrahepatic levels of DuIFN-g mRNA. Intrahepatic levels of DuIFN-g were
quantiﬁed by real-time RT-PCR in necropsy liver samples (week 40) of all animals
and normalized against the b-actin gene. The black horizontal line indicates the
baseline level of DuIFN-g mRNA in uninfected duck livers. Statistically signiﬁcant
differences in the EP group relative to the SI group and to the control group are
shown ** (po0.01).
Fig. 6. Immunohistochemical detection of DHBV preS-positive hepatocytes and CD3-po
and CD3 antigen (lower panel) was visualized in liver samples from ducks that represe
typical proﬁle of chronic DHBV infection (A). The EP-treated ducks no. 440 and 454
respectively). A complete resolution of DHBV infection was observed in duck no. 474 fro
arrows indicate cells expressing DHBV preS protein.These results suggest a signiﬁcant beneﬁt of EP-based pDNA
delivery in its ability to enhance the Th1 cytokine response in the
liver and the cccDNA clearance.
Immunohistochemical analysis of liver samples
Next, we examined the inﬁltration of CD3þ T cells and DHBV
pre-S protein expression in necropsy liver samples of all animals
and we correlated their immunohistological proﬁles with their
serum and liver virus clearance. This comparison revealed differ-
ent proﬁles of viral clearance as illustrated in Fig. 6 and summar-
ized in Table 1. All ﬁve control ducks and two (nos. 470 and 473)
out of 5 ducks from the SI-treated group, exhibiting a typical
serological proﬁle of chronic DHBV infection that is characterized
by high viral load and very weak or narrow B-cell response,
showed a massive expression of DHBV pre-S in virtually all
hepatocytes and a mild portal lymphocyte inﬁltration (as illu-
strated in Fig. 6 A for duck no. 470). By contrast, a different proﬁle
was observed for three responder animals (nos. 448, 458 and 468)
from the SI-treated group and four ducks (nos. 440, 452, 459 and
475) from EP-treated group exhibiting lower viremia and higher
anti-preS response than those of the control ducks at the end of
the follow-up, suggesting a partial viral clearance (Table 1). Thus,
immunoperoxidase staining of liver samples from these animals
showed the presence of clusters of cells expressing DHBV preS
antigen and a moderate to marked portal inﬁltration as illustrated
for duck no. 440 from EP group (Fig. 6B, Table 1). A particularly
interesting proﬁle was observed for duck no. 454, from the EP-
treated group, which cleared viremia relatively late (week 37)
concomitantly with development of a high anti-preS response.
This animal showed a residual DHBV preS antigen expression
limited to only few hepatocytes and exhibited a marked portal
lymphocyte inﬁltration that correlated with very high levels of
DuIFN-g expression in its liver, suggesting an advanced stage of
clearance (Fig. 6C). An even more complete stage of clearance was
observed for duck no. 474 from this group that completely cleared
viremia at an early stage, by week 10, concomitantly with
seroconversion to a sustained anti-preS response and undetect-
able levels of cccDNA by the end of the therapy. Interestingly, thesitive cells in necropsy liver samples. Expression of viral preS protein (upper panel)
nt different proﬁles of infection resolution. SI-treated duck no. 470 represented a
represented a partial and an advanced stage of clearance, respectively (B and C,
m the EP-treated group (D). Nuclei were counterstained with haematoxylin. Black
Table 1
Summary of intrahepatic DHBV preS expression and portal CD3þ cells inﬁltration.
Group DHBV infection proﬁlea Duck I.D % of DHBpreS positive hepatocytesb Portal inﬁltrationc
EP-treated Partial clearance 440, 452, 475, 459 30–50 (clusters) þþ to þþþ
Advanced clearance 454 o1 þþþ
Complete clearance 474 o0.001 þþ
Chronic infection – – –
SI-treated Partial clearance 448, 458, 468 30–50 (clusters) þþ to þþþ
Chronic infection 470, 473 490 þ
Control Chronic infection 431, 457, 441, 462, 467 490 þ
a Different status of chronic DHBV infection.
b The DHBpreS-positive hepatocytes were determined by immunoperoxidase staining of liver tissue.
c Portal inﬁltration of CD3þ T cells was determined by immunoperoxidase staining and graded semi-quantitatively as: þ , mild;þþ, moderate;
þþþ marked.
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tectable DHBV preS expression and a moderate portal lymphocyte
inﬁltration, indicating an earlier clearance of infection (Fig. 6D).
Such complete viral clearance was not observed in animals from
SI-treated ducks and controls (Table 1). Collectively these results
indicate that in spite of individual differences, more advanced
degree of viral clearance was observed in the EP-treated group.
Adverse effects of therapy
Histological analysis of all duck liver samples did not show
severe lesions, necrosis or fulminant hepatitis. Occasional pre-
sence of amyloidosis and frequent steatosis, known to occur in
adult Pekin ducks (Cova et al., 1990), was observed regardless of
treatment group. Even though several deaths have occurred
during this long-term experiment (10 months), they were acci-
dental and their incidence rate was similar between the SI, EP and
control groups, indicating that these deaths were not related to
the treatment (two deaths per group, excluded from the study).
These data indicates the absence of side effects for the treatment
we used at the described conditions.Discussion
In this study, we report for the ﬁrst time that EP-based
delivery enhanced the therapeutic efﬁcacy of DNA-based vaccina-
tion in terms of both viral clearance and breaking of immune
tolerance in hepadnaviral-carriers, suggesting a beneﬁt of this
approach for chronic hepatitis B therapy. We used in this study
co-immunization with DuIFN-g encoding plasmid, since we have
previously shown that co-delivery of DuIFN-g gene with the DHBV
DNA vaccine led to the enhancement of the humoral anti-preS
response in naı¨ve animals (Saade et al., 2008) and increased
therapeutic efﬁcacy of DNA vaccine in DHBV-carriers (Saade
et al., 2011). The EP-delivered DHBV DNA vaccine was particularly
effective, leading to a marked decrease in viremia in all animals. In
contrast, delivery of the same vaccine by SI was less effective since
2 out of 5 ducks had similar viremia levels as those of the controls.
The mean viremia levels in the EP-treated group was consistently
lower and reached a signiﬁcant difference starting at week 31 p.i.
until the end of the follow-up, as compared to control ducks and
SI-treated ducks. Importantly, EP-based pDNA therapy led to
viremia clearance in 33% of animals (2 out of 6 ducks) whereas
none of the SI-treated ducks or the control ducks cleared viral DNA
levels in their sera. Moreover, the effects of the EP-based pDNA
therapy on DHBV replication were sustained since no rebound in
viremia was observed during 4 weeks after immunotherapy
cessation in the 2 EP-treated ducks that cleared viral replication.
Interestingly, within these two EP-treated animals, duck no. 474,which cleared viremia after only three DNA immunizations
and duck no. 454, exhibiting a relatively late viremia clearance,
completely eliminated or presented very low intrahepatic DHBV
DNA intermediates, respectively.
Because studies in animal models and in chronically infected
patients demonstrated the crucial role of the hepadnaviral
cccDNA pool in the persistence and reactivation of virus replica-
tion (Le Mire et al., 2005; Mason et al., 1994; Werle-Lapostolle
et al., 2004), it was of particular importance to precisely quantify
the cccDNA levels in apparently resolved animals, using a highly
sensitive quantitative PCR assay. We report here that an early
drop in viremia was correlated with complete liver DHBV DNA
clearance, including cccDNA, i.e. level below the cut-off of detec-
tion by the qPCR assay, as observed for duck no. 474. In contrast, a
relatively late drop in viremia was associated with an advanced
stage of intrahepatic viral DNA clearance represented by only
traces of cccDNA (0.08 copies of cccDNA/cell for duck no. 454),
which is consistent with our previous observations in another
DNA vaccination-based therapeutic protocol in DHBV-carriers
(Thermet et al., 2008). The low pre-treatment viral load observed
for these two ducks may contribute to their advanced or complete
stage of viral clearance as previously reported by us (Le Guerhier
et al., 2003). Furthermore, intrahepatic viral cccDNA levels were
found to be signiﬁcantly reduced only in the EP-treated group as
compared with control group, suggesting a marked beneﬁt of EP
based pDNA delivery in terms of decrease and even clearance of
cccDNA pool in these DHBV-carriers.
The effect of EP-based pDNA delivery on restoring the anti-
preS antibody response in DHBV-carriers was remarkable. In fact,
this pDNA delivery method was associated with a strong and
sustained seroconversion to anti-preS response in all animals that
was signiﬁcantly higher (po0.05) during the last 11 weeks as
compared to other groups. We observed the presence of viral
particles in some animal sera despite the presence of anti-preS
antibodies, which may be likely related to the circulating immune
complexes. Interestingly, an early seroconversion to high anti-
preS titers was observed only in the 2 EP-treated ducks that
cleared viral DNA from their sera and had either undetectable or
traces of cccDNA in their liver, whereas a more delayed and lower
anti-preS response was observed in animals that showed a
decrease in viral load only at the end of the follow-up. Thus,
these results suggest that viral clearance is tightly associated with
an early induction of the humoral response.
Even though the mechanism of viral clearance is thought to be
a Th1-cell dependent process, the antibody response to hepadna-
viral infection is known to play a critical role in viral clearance by
neutralizing free viral particles in the circulation and by prevent-
ing their attachment and uptake by hepatocytes (Chisari et al.,
2010). In the case of DHBV, we and others have previously
showed that anti-preS antibodies play an important role in
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action with host cell receptors (Sunyach et al., 1999; Urban et al.,
2000). In addition, Zhang and Summers, 2004 have shown that
neutralizing anti-preS antibodies prevented secondary cycles of
infection, resulting in limited intrahepatic virus spread. Therefore,
using the peptide scanning approach, we explored, in this study,
the epitope pattern, particularly the neutralizing epitopes, of
antibodies generated in all animals at the end of the follow-up.
We report here that all sera from EP-treated ducks recognized a
broad range of neutralizing epitopes. Indeed, these sera recog-
nized 14 major ARs of the DHBV L protein, almost in the same
manner as ducks that eliminated DHBV replication. Moreover,
such mutli-speciﬁc B-cell response is similar to that observed
recently by us in naı¨ve ducks immunized by EP with DNA vaccine
targeting DHBV envelope (Khawaja et al., 2012). Importantly, the
highly recognized ARs included several DHBV neutralization
epitopes 12R-P30, 41P-T52, 58T-W65, 83I-P90, 100F-R107, 112T-P120
and 123K-G133 previously identiﬁed by us and others (Chassot
et al., 1993; Chassot et al., 1994; Yuasa et al., 1991). By contrast,
the reactivity spectrum of sera within the SI-treated group
appeared narrower, less intense and was restricted to a few ARs,
including only a subset of neutralizing epitopes as compared to
sera from EP-treated ducks. These results suggest a signiﬁcant
beneﬁt of EP-based pDNA delivery to stimulate, in all DHBV-
carriers, a broadly reactive humoral response to DHBV preS
protein that probably contributed to decreased/cleared viral load
in these animals as compared to other groups.
At the end of follow-up, intrahepatic expression of IFN-g,
known to play a key role in the mechanism of HBV clearance
through a non-cytolytic pathway (Hodgson and Michalak, 2001;
Wieland et al., 2004) was investigated in all animals using a
quantitative real-time RT-PCR assay. Using this approach, we
have previously demonstrated that the resolution of transient
DHBV infection is concomitant with an extremely rapid rise of
intrahepatic DuIFN-g RNA levels, which is thereafter followed by
a decrease (Narayan et al., 2006). We demonstrate here that EP-
treated group had signiﬁcantly higher mean intrahepatic DuIFN-g
RNA levels than those of the SI-treated group and the control
group (po0.001). Although all EP-treated ducks exhibited a break
of immune tolerance, the fact that not all of them resolved the
infection could be explained by the relatively late induction of
anti-preS antibody response and the late expression of DuIFN-g
response. Interestingly, the highest DuIFN-g RNA level observed
for EP-treated duck (no. 454) was associated with the late drop in
viremia, the strong seroconversion to anti-preS, the presence of
traces of cccDNA and a marked portal inﬁltration, therefore
conﬁrming that this animal was in an advanced stage of infection
clearance. Thus, our ﬁndings suggest a signiﬁcant beneﬁt of EP-
based pDNA delivery for restoration of the intrahepatic IFN-g
response in all DHBV-carriers that may contribute to viral
clearance from their livers. We were unable to monitor other
features of the Th1 response in this study, since the tools for
analysis of duck cellular response are still under development
(_ENREF_34_ENREF_34).
The safety of an intensive therapeutic protocol including 12
injections of HB-100 DNA vaccine at 4 weeks interval has been
previously reported in chronic hepatitis B carriers (Yang et al.,
2006). In addition, the safety of the EP delivery method has been
demonstrated in multiple animal models (van Drunen Littel-van
den Hurk and Hannaman, 2010) as well as in recent clinical
studies in humans (Sallberg et al., 2009; Vasan et al., 2011). In our
study, multiple DNA injections delivered by EP or SI at 3–4 weeks
interval were performed to break immune tolerance in DHBV-
carriers. This therapeutic protocol was well tolerated in all DHBV-
carriers and no particular adverse effects were associated with
this therapy. Histological analysis of duck liver samples at the endof the follow-up period showed changes limited to different
degrees of portal lymphocyte inﬁltrations ranking from mild to
marked portal inﬁltrations. EP-treated ducks showed high expres-
sion of DuIFN-g that was associated with a moderate to marked
lymphocyte inﬁltration in the liver, but no necroinﬂammation
was observed. The histological and serological proﬁle of EP-
treated ducks, at the end of the follow-up, was similar to that
observed during natural resolution of DHBV infection in ducks
which was associated with only a mild liver disease with no
evidence of signiﬁcant cell death contributing to viral clearance
(Jilbert et al., 1992). Concerning the persistence of DNA in
muscles, we have previously reported that following EP-delivery
of a pCI-preS/S DNA vaccine, the expression of DHBV pre-S
antigen is still detectable at the injection site in the muscle ﬁbers
at day 6 p.i. (Khawaja et al., 2012). After this time point, antigen
expression decreases and becomes undetectable at day 12 p.i.
suggesting a decrease in plasmid DNA copy numbers at the
injection site in the muscles (unpublished observation). In the
current long-term follow-up study, we were unable to examine
the persistence of DNA in muscles after necropsy and its potential
integration in genomic DNA. However, published studies in
animal models and clinical trials have reported no adverse events
following DNA administration by EP (Dolter et al., 2011). Tissue
biodistribution studies in animals have reported that after
EP-based DNA delivery, plasmid DNA is present only at the
injection site. There is a rapid decrease in plasmid copy numbers
over time and early concerns surrounding plasmid integration
into the host genome remain unsubstantiated (Luckay et al.,
2007; Roos et al., 2009).
In conclusion, this preclinical study provides the ﬁrst report on
the beneﬁt of EP-based pDNA delivery, able to markedly restore
multi-speciﬁc B-cell response and to sustainably decrease and
even clear viral infection in chronic hepadnavirus-carriers. Addi-
tional improvements in the therapeutic protocol of EP-based
pDNA delivery should be carried out such as optimization of the
vector construct so as to minimize the amount of the pDNA that
needs to be delivered, evaluation of the number of DNA injec-
tions/sites, and the immunization schedule. Since our results
represent the net effect of DNA vaccine, the combination of EP-
based pDNA delivery with approved antiviral treatments (Teno-
fovir, Entecavir) deserves to be further investigated. Thus a ﬁrst
clinical trial showed already encouraging results (Yang et al.,
2012), indicating that further studies exploring such novel DNA
EP-based combination therapies in animal models of hepadna-
virus infection are warranted for future applications in clinic.Materials and methods
Animals
Chronic DHBV-carrier ducks were obtained by intravenous
inoculation of 3-day-old Pekin ducklings with a viremic serum
pool (21010 viral genome equivalents (vge) per animal) as
described previously (Cova and Zoulim, 2004; Rollier et al.,
1999). Animal experimentation was performed in accordance
with the guidelines for animal care of the ethical committee at
the National Veterinary School of Lyon (Marcy l’Etoile, France).
Plasmid expression vectors
pCI-preS/S, pCI-C, pCI-IFNg plasmids were constructed and
veriﬁed for the expression of DHBV preS/S, core, and DuIFN-g
respectively, as described previously (Rollier et al., 1999; Saade
et al., 2008; Thermet et al., 2004). Plasmids were puriﬁed using
Endotoxin-Free Giga Prep (Qiagen, Hilden, Germany).
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Three weeks after hatching, the DHBV positivity of each duck
was assessed by dot blot hybridization. DHBV-infected ducks
were randomly assigned into 3 groups, which were intramuscu-
larly (i.m) injected with a total of 600 mg of pDNA. Treated groups
received i.m. injections of pCI-preS/S, pCI-C and pCI-FN-g deliv-
ered either by a TriGrid electroporation (EP) device (Ichor Medical
Systems, San Diego, CA) (group EP, n¼6) or by standard injection
(group SI, n¼5). A control group included untreated ducks (n¼3)
and pCI (empty plasmid, n¼2) injected ducks via EP was followed
up in parallel. The DNA injections were performed in two sites; in
breast and shoulder. EP was applied after general anesthesia with
a four-needle electrode array using the TriGrid delivery device,
with 6 mm intraelectrode spacing and electrical stimulation at
amplitude of 250 V/cm. The total duration of electrical stimula-
tion was 40 ms, applied over a 400 ms interval. Booster doses
were administered at week 6, 9, 16, 21, 25, 29, 33 and 36 post-
hatching. After the last immunization, animals were followed
during additional 4 weeks and were thereafter sacriﬁced. Autopsy
liver samples were snap-frozen in liquid nitrogen and stored at
80 1C before use for analysis described below.
Serological assays
Viremia was assessed by quantitative detection of DHBV DNA
in duck serum using dot blot hybridization assay described
elsewhere (Cova and Zoulim, 2004; Le Guerhier et al., 2000).
The anti-preS antibody titers were determined on serum
samples from each duck at each time point of follow-up using
an end-point dilution ELISA titration assay described previously
(Chassot et al., 1994; Rollier et al., 2000).
Screening of induced antibodies in ducks for pre-S B-cell epitopes
recognition
The antibody response of individual duck sera to DHBV pre-S
linear epitopes were analyzed using the PEPSCAN method
(Khawaja et al., 2012). Brieﬂy, a pepset of 77 9-mers peptides
with an overlap of 7 amino acids, spanning the entire DHBV pre-S
protein (residues 1–166) was synthesized by Mimotopes peptide
company (UK) in the format Biotin-SGSG-PEPTIDE-amide. Each
duck serum taken at week 40 was tested for peptide binding as
described previously in details (Khawaja et al., 2012).
Analysis of intrahepatic viral DNA replication
Frozen necropsy liver samples were submitted to two inde-
pendent DNA extraction procedures for isolation of total viral
DNA (protein bound) and for cccDNA (non-protein bound) as
described previously (Le Guerhier et al., 2000) and then quantiﬁed
by spectrophotometry. 10 mg of DNA obtained by each prepara-
tion were then subjected to Southern blot analysis as described
previously (Cova and Zoulim, 2004).
For viral cccDNA quantiﬁcation by real-time PCR, 500 ng of
DNA were subjected to Plasmid-SafeTM ATP-dependent DNase
(Epicentre, Madison, USA) digestion according to manufacturer’s
recommendations before PCR ampliﬁcation. For real-time PCR
analysis, 4 ml of digestion product was ampliﬁed in 1 SYBR
green Supermix (Bio-Rad) containing 20 pmol of each primer
(DHBV2456F 50-CCTGATTGGACGGCTTTTC-30 and DHBV2687R
50-TCATACACACATTGGCTAAGGCTC-30) (Thermet et al., 2008).
The PCR ampliﬁcation cycle included 40 cycles: denaturation
94 1C for 20 s, annealing at 58 1C for 15 s, and elongation at
72 1C for 30 s. Determination of copy number of cccDNA was
performed according to a standard curve based on agarose gelpuriﬁed EcoRI-cleaved DHBV genome containing plasmid. The
sensitivity of this assay for cccDNA detection was 0.0001 copies/
cell. The copy number of DHBV DNA per cell was calculated
according toLe Mire et al., 2005.
Quantiﬁcation of DuIFN-g RNA in liver samples by real-time PCR
Total RNA was extracted from liver samples, pulverized under
liquid nitrogen, using a NucleoSpin RNA II kit (Macherey-Nagel)
and treated with DNase according to the manufacturer’s instruc-
tions. RNA was quantiﬁed by spectrophotometry and subse-
quently ﬁrst-strand cDNA was synthesized from 1 mg total RNA
using the SuperScript III Reverse Transcriptase kit (Invitrogen)
and primed with random hexamer and oligo-(dT) primers accord-
ing to the manufacturer’s protocol. Reactions were performed at
50 1C for 30 min and then consecutively for 5 min at 85 1C and at
4 1C, respectively. 4 ml of the RT reactions were used as a template
for real-time PCR. The ampliﬁcation was performed in a MyiQ
system (Bio-Rad) with SYBR Green Supermix Kit (Bio-Rad) under
the same conditions than those previously described by Narayan
et al., 2006 with the selective primers for DuIFN-g (forward,
50-CAAGTAATTCGGATGTAGC-30 and reverse, 50-GCGTTGGATTTT-
CAAGCC-30). The reaction was standardized using 10-fold serial
dilutions (1108 copies to 1 copy) of pCI-DuIFN-g plasmid
samples as described previously in detail (Narayan et al., 2006).
All samples from infected and uninfected ducks were tested in
duplicate and run together. The detection limit of this assay was
estimated to 1 copy of amplicon DNA per reaction. The assay was
normalized against the housekeeping gene b-actin tested in the
same samples using primers derived from the duck b-actin
sequence (forward, 50-GGTGATGAAGCTCAGAGCAA-30; reverse,
50-CTCCTCAGGGGCTACTCTCA-30).
Immunohistolochemical analysis of liver samples
Five mm thickness formalin-ﬁxed liver tissue sections were
stained with hematoxylin–eosin–safran and examined under a
light microscope. The level of hepatocyte necrosis (acidopholic
bodies), steatosis, portal tract and intralobular inﬂammation were
assessed semi-quantitatively under code (i.e. in a blinded man-
ner). Liver sections were analyzed for DHBV pre-S antigen
expression and for CD3þ T cells inﬁltration by immunohisto-
chemistry. Tissue sections were stained with a previously
described rabbit polyclonal antiserum raised against DHBpre-S
polypeptide (Lambert et al., 1991) or with an antibody to human
CD3 (Clone F7.2.38, DakoCytomation). All slides were counter-
stained with haematoxylin.
Statistical analysis
The efﬁciency of therapies on viremia, anti-preS titers and liver
viral cccDNA levels of experimental groups were compared using
the nonparametric Mann–Whitney U test to determine the sig-
niﬁcance between groups. These statistical analyses were per-
formed using GraphPad Prism 4.0 software (San Diego, CA).
P valueso0.05 were considered statistically signiﬁcant.Acknowledgments
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